1. AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9
   Dongpo Cai et al, 2006, Cancer Research CrossRef
2. The Role of Kinase Inhibitors in Cancer Therapies
   Gizem Kursunluoglu et al, 2021, Protein Kinases - Promising Targets for Anticancer Drug Research CrossRef
3. From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
   Zhenfeng Shi et al, 2022, Journal of Medicinal Chemistry CrossRef
4. Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
   Raoul Tibes et al, 2019, Frontiers in Oncology CrossRef
5. Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
   Walter M. Stadler et al, 2000, Journal of Clinical Oncology CrossRef
6. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
   Glenn Liu et al, 2004, Clinical Cancer Research CrossRef
7. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of γH2AX foci
   Kevin Camphausen et al, 2004, Molecular Cancer Therapeutics CrossRef
8. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
   Tapan Mahendra Kadia et al, 2019, Oncotarget CrossRef
9. CDK1 in Breast Cancer: Implications for Theranostic Potential
   Sepideh Izadi et al, 2020, Anti-Cancer Agents in Medicinal Chemistry CrossRef
10. Exploring the anti‐cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review
    Md Sohel et al, 2023, Cancer Medicine CrossRef
11. Transcriptional signature of flavopiridol-induced tumor cell death
    Xing Lü et al, 2004, Molecular Cancer Therapeutics CrossRef
12. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
    Geoffrey I. Shapiro, 2006, Journal of Clinical Oncology CrossRef
13. Meta-Analysis of Esophageal Cancer Transcriptomes Using Independent Component Analysis
    Ainur Ashenova et al, 2021, Frontiers in Genetics CrossRef
14. Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation
    Maura Puppo et al, 2004, Clinical Cancer Research CrossRef
15. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
    Yuming Zhang et al, 2024, Journal of Medicinal Chemistry CrossRef
16. Flavopiridol Blocks Integrin-Mediated Survival in Dormant Breast Cancer Cells
    Saltanat Najmi et al, 2005, Clinical Cancer Research CrossRef
17. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1)
    Sven Marcel Schmitt et al, 2016, Journal of Medicinal Chemistry CrossRef
18. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy
    Yean Kit Lee et al, 2006, Molecular Cancer Therapeutics CrossRef
19. Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
    Antoinette R. Tan et al, 2002, Journal of Clinical Oncology CrossRef
20. Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol
    Geoffrey I. Shapiro, 2004, Clinical Cancer Research CrossRef
21. Highly Enantioselective Nickel-Catalyzed Intramolecular Hydroalkenylation of N- and O-Tethered 1,6-Dienes To Form Six-Membered Heterocycles
    Ke Li et al, 2018, Journal of the American Chemical Society CrossRef
22. De novo transcriptome analysis of Dysoxylum binectariferum to unravel the biosynthesis of pharmaceutically relevant specialized metabolites
    Patel Mohana Kumara et al, 2023, Frontiers in Plant Science CrossRef
23. Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study
    James A. Whitlock et al, 2005, Journal of Clinical Oncology CrossRef
24. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy
    Steven Grant et al, 2003, Drug Resistance Updates CrossRef
25. Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
    Keith C. Bible et al, 2005, Clinical Cancer Research CrossRef
26. Discovery of Pongol, the Furanoflavonoid, as an Inhibitor of CDK7/Cyclin H/MAT1 and Its Preliminary Structure–Activity Relationship
    Deendyal Bhurta et al, 2023, ACS Omega CrossRef